Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis.
Neres, J., Pojer, F., Molteni, E., Chiarelli, L.R., Dhar, N., Boy-Rottger, S., Buroni, S., Fullam, E., Degiacomi, G., Lucarelli, A.P., Read, R.J., Zanoni, G., Edmondson, D.E., De Rossi, E., Pasca, M.R., McKinney, J.D., Dyson, P.J., Riccardi, G., Mattevi, A., Cole, S.T., Binda, C.(2012) Sci Transl Med 4: 150ra121-150ra121
- PubMed: 22956199 
- DOI: 10.1126/scitranslmed.3004395
- Primary Citation of Related Structures:  
4AUT, 4F4Q - PubMed Abstract: 
The benzothiazinone BTZ043 is a tuberculosis drug candidate with nanomolar whole-cell activity. BTZ043 targets the DprE1 catalytic component of the essential enzyme decaprenylphosphoryl-β-D-ribofuranose-2'-epimerase, thus blocking biosynthesis of arabinans, vital components of mycobacterial cell walls ...